|
1
|
Li MC, Lee NY, Lee CC, Lee HC, Chang CM
and Ko WC: Pneumocystis jiroveci pneumonia in immunocompromised
patients: Delayed diagnosis and poor outcomes in
2014,non-HIV-infected individuals. J Microbiol Immunol Infect.
47:42–47. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mansharamani NG, Garland R, Delaney D and
Koziel H: Management and outcome patterns for adult pneumocystis
carinii pneumonia, 1985 to 1995: Comparison of HIV-associated cases
to other immunocompromised states. Chest. 118:704–711. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Miller RF, Allen E, Copas A, Singer M and
Edwards SG: Improved survival for HIV infected patients with severe
pneumocystis jirovecii pneumonia is independent of highly active
antiretroviral therapy. Thorax. 61:716–721. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yale SH and Limper AH: Pneumocystis
carinii pneumonia in patients without acquired immunodeficiency
syndrome: Associated illness and prior corticosteroid therapy. Mayo
Clin Proc. 71:5–13. 1996. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Weng L, Huang X, Chen L, Feng LQ, Jiang W,
Hu XY, Peng JM, Wang CY, Zhan QY and Du B: Prognostic factors for
severe Pneumocystis jirovecipneumonia of non-HIV patients in
intensive care unit: A bicentric retrospective study. BMC
Infectious Dis. 16:5282016. View Article : Google Scholar
|
|
6
|
Monnet X, Vidal-Petiot E, Osman D,
Hamzaoui O, Durrbach A, Goujard C, Miceli C, Bourée P and Richard
C: Critical care management and outcome of severe Pneumocystis
pneumonia in patients with and without HIV infection. Crit Care.
12:R282008. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Boonsarngsuk V, Sirilak S and Kiatboonsri
S: Acute respiratory failure due to pneumocystis pneumonia: Outcome
and prognostic factors. Int J Infect Dis. 13:59–66. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang JC, Dai JY, Fan J and Wu XP: The
treatment of pneumocystis Carinii pneumonia with caspofungin in
elderly patients: A case report and literature review. Zhonghua Jie
He He Hu Xi Za Zhi. 29:4632006.(In Chinese). PubMed/NCBI
|
|
9
|
Annaloro C, Volpe AD, Usardi P and
Lambertenghi Deliliers G: Caspofungin treatment of Pneumocystis
pneumonia during conditioning for bone marrow transplantation. Eur
J Clin Microbiol Infect Dis. 25:52–54. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Beltz K, Kramm CM, Laws HJ, Schroten H,
Wessalowski R and Göbel U: Combined trimethoprim and caspofungin
treatment for severe pneumocystis jiroveci pneumonia in a five year
old boy with acute lymphoblastic leukemia. Klin Pädiatr.
218:177–179. 2006. View Article : Google Scholar
|
|
11
|
Kamboj M, Weinstock D and Sepkowitz KA:
Progression of pneumocystis jiroveci pneumonia in patients
receiving echinocandin therapy. Clin Infect Dis. 43:e92–e94. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Takeda K, Morioka D, Kumamoto T, Matsuo K,
Tanaka K, Endo I, Togo S and Shimada H: A survival case of
ABO-incompatible liver transplantation complicated with severe
preoperative infection and subsequent overwhelming postsplenectomy
infection. Transplant Proc. 41:3941–3944. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang W, Wang GF, Nie LG, et al: Clinical
characteristics of Pneumocystis pneumonia during chemotherapy and
radiotherapy in lung cancer patients. J Prac Oncol. 27:175–179.
2012.
|
|
14
|
Li H, Huang H and He H: Successful
treatment of severe Pneumocystis pneumonia in an immunosuppressed
patient using caspofungin combined with clindamycin: A case report
and literature review. BMC Pulm Med. 16:1442016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim T, Hong HL, Lee YM, Sung H, Kim SH,
Choi SH, Kim YS, Woo JH and Lee SO: Is caspofungin really an
effective treatment for pneumocystis jirovecii pneumonia in
immunocompromised patients without human immunodeficiency virus
infection? Experiences at a single center and a literature review.
Scand J Infect Dis. 45:484–488. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tu GW, Ju MJ, Xu M, Rong RM, He YZ, Xue
ZG, Zhu TY and Luo Z: Combination of caspofungin and low-dose
trimethoprim/sulfamethoxazole for the treatment of severe
pneumocystis jirovecii pneumonia in renal transplant recipients.
Nephrology (Carlton). 18:736–742. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jiang XQ, Fang L, Mei XD, Wang XJ and Bao
MH: Pneumocystis jiroveci pneumonia in patients with non-Hodgkin's
lymphoma after Rituximab-containing regimen: Two cases of report
and literature review. J Thorac Dis. 5:E162–E166. 2013.PubMed/NCBI
|
|
18
|
Mu XD, Que CL, He B, Wang GF and Li HC:
Caspofungin in salvage treatment of severe pneumocystis pneumonia:
Case report and literature review. Chin Med J (Engl). 122:996–999.
2009.PubMed/NCBI
|
|
19
|
Hof H and Schnülle P: Pneumocystis
jiroveci pneumonia in a patient with Wegener's granulomatosis
treated efficiently with caspofungin. Mycoses. 1 Suppl:S65–S67.
2008. View Article : Google Scholar
|
|
20
|
Utili R, Durante-mangoni E, Basilico C,
Mattei A, Ragone E and Grossi P: Efficacy of caspofungin addition
to trimethoprim-sulfamethoxazole treatment for severe pneumocystis
pneumonia in solid organ transplant recipients. Transplantation.
84:685–688. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Schmatz DM, Romancheck MA, Pittarelli LA,
Schwartz RE, Fromtling RA, Nollstadt KH, Vanmiddlesworth FL, Wilson
KE and Turner MJ: Treatment of pneumocystis carinii pneumonia with
1,3-beta-glucan synthesis inhibitors. Proc Natl Acad Sci USA.
87:5950–5954. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Armstrongjames D, Stebbing J, John L,
Murungi A, Bower M, Gazzard B and Nelson M: A trial of caspofungin
salvage treatment in PCP pneumonia. Thorax. 66:537–538. 2011.
View Article : Google Scholar
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Smego RA Jr, Nagar S, Maloba B and Popara
M: A Meta-analysis of salvage therapy for pneumocystis carinii
pneumonia. Arch Intern Med. 161:1529–1533. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kim T, Kim SH, Park KH, Cho OH, Sung H,
Kim MN, Choi SH, Jeong JY, Woo JH, Kim YS and Lee SO:
Clindamycin-primaquine versus pentamidine for the second-line
treatment of pneumocystis pneumonia. J Infect Chemother.
15:343–346. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Powles MA, Liberator P, Anderson J,
Karkhanis Y, Dropinski JF, Bouffard FA, Balkovec JM, Fujioka H,
Aikawa M, McFadden D and Schmatz D: Efficacy of MK-991 (L-743,872),
a semisynthetic pneumocandin, in murine models of Pneumocystis
carinii. Antimicrob Agents Chemother. 42:1985–1989. 1998.PubMed/NCBI
|
|
27
|
Thomas CF Jr and Limper AH: Current
insights into the biology and pathogenesis of Pneumocystis
pneumonia. Nat Rev Microbiol. 5:298–308. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lobo ML, Esteves F, De SB, de Sousa B,
Cardoso F, Cushion MT, Antunes F and Matos O: Therapeutic potential
of caspofungin combined with trimethoprim-sulfamethoxazole for
pneumocystis pneumonia: A pilot study in mice. PLoS One.
8:e706192013. View Article : Google Scholar : PubMed/NCBI
|
